Nuchev (ASX:NUC) — Material Events
ASX:NUC · 9 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Nuchev Doubles Revenue, Narrows Losses, and Expands into VietnamMedium
Nuchev doubles revenue in FY25, narrows losses, expands into Vietnam and Practitioner channel
28 Aug 2025
·Full Year Report and Appendix 4E
·85
Nuchev’s Record Revenue Surge Fuels Expansion in Vietnam and AustraliaMedium
Nuchev posts record Q4 revenue, expands via agency deal, eyes breakeven
24 July 2025
·Quarterly Activity Report and Appendix 4C
·85
Nuchev Accelerates Growth with 30% Revenue Surge and Vietnam Market EntryMedium
Nuchev posts 30% revenue growth in Q1 FY26 with expansion into Vietnam and strong channel diversification
30 Oct 2025
·Quarterly Activity Report and Appendix 4C
·80
Nuchev Doubles Revenue to $22.9m as Oli6® Expands Across AsiaMedium
Nuchev doubles revenue to $22.9m in FY25 with strong Oli6® growth and bWellness integration; adjusted EBITDA loss narrows
28 Aug 2025
·Full Year Results
·80
Nuchev Boosts Margins and Control with New Distribution DealMedium
Nuchev shifts to distribution model with H&S to boost margins and scale growth
4 Mar 2026
·ASX Market Release
·75
Nuchev Secures $2M Facility to Accelerate Growth AmbitionsMedium
Nuchev secures $2 million working capital facility from major shareholders to fund growth
30 Oct 2025
·Capital Raising
·70
Nuchev Grows Revenue 12% but Loss Widens as Expansion Costs BiteMedium
Nuchev Limited H1 FY2026: Revenue up 12%, net loss widens to $2.34M amid growth investments
24 Feb 2026
·Appendix 4D Half-year report
·70
H&S Group Boosts Stake in Nuchev with $1.9M Capital InjectionMedium
H&S Group exercises performance options, increasing stake in Nuchev to 48.62% and injecting $1.9M capital
25 July 2025
·Equity Raising / Share Issue
·65
No articles in this tier for the last 12 months.